Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


123456>>>
145 Items
Title  Creator  Group name  Publishing year 
[Molecular signatures in castration-resistant prostate cancers: An update] Houédé and Pourquier EquipeCG 2022-07-21
[Locally advanced or metastatic bladder cancer: Identification of barriers and levers of patients' pathway in France] Houédé et al. EquipeCG 2022-06-17
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie] Rollin et al. EquipeCG 2022-04
[Development of a therapeutic education program for prostate cancer patients undergoing new generation hormone therapy] Cuenant et al. EquipeCG 2022-05
Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug-Drug Interactions Are the Usual Suspects Leenhardt et al. EquipeCG 2022-04-11
Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Vano et al. EquipeCG 2022-05
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry Vezzio-Vié et al. EquipeCG 2022-05-20
Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer Viganò et al. EquipeCG 2022-05-13
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma Italiano et al. EquipeCG 2022-02
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study Siefker-Radtke et al. EquipeCG 2022-02
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer Smith et al. EquipeCG 2022-03-24
Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study Vano et al. EquipeCG 2022-10-15
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia Xiong et al. EquipeCG 2021
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1 Matheux et al. EquipeCG 2021-07-20
Inventaire des lésions de l'ADN et principaux mécanismes de réparation de l'ADN Pourquier EquipeCG 2021-03
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells Corvaglia et al. EquipeCG 2021-06-28
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures Larbouret et al. EquipeCG 2021-09-15
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial Culine et al. EquipeCG 2021-12
BAG6 promotes PINK1 signaling pathway and is essential for mitophagy Ragimbeau et al. EquipeCG 2021-02
Anticancer Drugs for Intra-Arterial Treatment of Colorectal Cancer Liver Metastases: In-Vitro Screening after Short Exposure Time Fohlen et al. EquipeCG 2021-07-01
Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models Rabia et al. EquipeCG 2021 Jan-Dec
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival Chauvin et al. EquipeCG 2021-07
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells Chauvin et al. EquipeCG 2021-01-26
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor Creusot et al. EquipeCG 2020-07-08
Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems Re?nik et al. EquipeCG 2020-11-15
123456>>>
145 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés